Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
Background: Data on the performance of newer biologics in patients with fistulizing Crohn’s disease (CD) are limited. Objective: Our study’s objective was to evaluate the response to ustekinumab (UST) and vedolizumab (VDZ) in patients with fistulizing CD. Design: Retrospective cohort. Methods: We us...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2023-03-01
|
| coleção: | Therapeutic Advances in Gastroenterology |
| Acesso em linha: | https://doi.org/10.1177/17562848221148254 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|